Emicizumab prophylaxis for people with hemophilia A: Waste estimation and the Brazilian perspective.

Saudi Pharm J · 2023 · PMC10661532 · PMID 38028212

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Since emicizumab is available in a few presentations and the regimens recommended by the manufacturer are rigid ( Mahlangu et al., 2022 , Srivastava et al., 2020 ), the product waste and associated costs may be significant.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.